Henry Schein, Inc.

WBAG:HSIC Stock Report

Market Cap: €8.2b

Henry Schein Valuation

Is HSIC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HSIC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HSIC (€67.08) is trading below our estimate of fair value (€68.61)

Significantly Below Fair Value: HSIC is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HSIC?

Key metric: As HSIC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for HSIC. This is calculated by dividing HSIC's market cap by their current earnings.
What is HSIC's PE Ratio?
PE Ratio27.7x
EarningsUS$314.00m
Market CapUS$8.60b

Price to Earnings Ratio vs Peers

How does HSIC's PE Ratio compare to its peers?

The above table shows the PE ratio for HSIC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average13.7x
1099 Sinopharm Group
7.3x4.0%HK$66.9b
601607 Shanghai Pharmaceuticals Holding
19.7x18.5%CN¥70.9b
000963 Huadong Medicine
19.6x13.2%CN¥62.9b
874 Guangzhou Baiyunshan Pharmaceutical Holdings
8x-0.4%HK$47.5b
HSIC Henry Schein
27.7x26.7%€8.6b

Price-To-Earnings vs Peers: HSIC is expensive based on its Price-To-Earnings Ratio (27.7x) compared to the peer average (13.7x).

Price to Earnings Ratio vs Industry

How does HSIC's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
HSIC 27.7xIndustry Avg. 18.0xNo. of Companies8PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: HSIC is expensive based on its Price-To-Earnings Ratio (27.7x) compared to the European Healthcare industry average (18.2x).

Price to Earnings Ratio vs Fair Ratio

What is HSIC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HSIC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio27.7x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate HSIC's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HSIC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€67.08
€71.50
+6.6%
9.7%€79.30€52.55n/a12
Dec ’25€73.62
€70.64
-4.0%
10.2%€78.37€51.93n/a11
Nov ’25€65.12
€69.11
+6.1%
10.2%€76.76€50.86n/a11
Oct ’25€65.04
€65.64
+0.9%
11.6%€74.35€49.27n/a11
Sep ’25€63.92
€67.87
+6.2%
13.2%€84.17€50.32n/a11
Aug ’25€66.66
€73.41
+10.1%
12.2%€85.10€55.50n/a11
Jul ’25€60.56
€74.05
+22.3%
9.6%€86.14€60.86n/a12
Jun ’25€63.60
€73.53
+15.6%
9.4%€85.18€60.18n/a12
May ’25€65.72
€75.78
+15.3%
7.8%€84.59€61.09n/a13
Apr ’25€70.36
€74.28
+5.6%
7.6%€82.21€59.37n/a13
Mar ’25€71.10
€73.94
+4.0%
7.8%€83.27€60.14n/a13
Feb ’25€68.96
€69.24
+0.4%
7.4%€75.54€59.88n/a12
Jan ’25€68.94
€68.54
-0.6%
7.3%€75.96€60.21n/a12
Dec ’24€63.26
€68.08
+7.6%
7.0%€75.38€59.75€73.6212
Nov ’24€60.28
€75.52
+25.3%
7.1%€85.17€65.29€65.1212
Oct ’24€70.14
€77.14
+10.0%
7.4%€89.00€65.33€65.0412
Sep ’24€70.86
€75.45
+6.5%
8.4%€87.44€62.85€63.9213
Aug ’24€72.34
€75.37
+4.2%
8.3%€86.86€62.43€66.6613
Jul ’24€74.08
€77.32
+4.4%
8.5%€89.36€64.23€60.5613
Jun ’24€68.74
€76.22
+10.9%
8.8%€87.43€62.84€63.6013
May ’24€73.12
€76.27
+4.3%
8.9%€87.83€62.48€65.7213
Apr ’24€74.24
€79.32
+6.8%
9.0%€91.97€65.42€70.3612
Mar ’24€72.37
€78.39
+8.3%
9.5%€90.98€64.72€71.1012
Feb ’24€79.18
€76.84
-3.0%
9.3%€92.02€65.07€68.9612
Jan ’24€74.84
€76.78
+2.6%
10.0%€93.27€65.95€68.9412
Dec ’23€78.26
€83.73
+7.0%
9.7%€101.50€72.80€63.2612

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 14:36
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/28
Annual Earnings2023/12/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Henry Schein, Inc. is covered by 38 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jeffrey JohnsonBaird
Ishan MajumdarBaptista Research
Lawrence MarshBarclays